Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVI-VAC
- Development stage
- Phase 3
- Lead developer
- Codagenix
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
COVI-VAC is a live attenuated, intranasal COVID-19 vaccine developed using codon-pair deoptimization technology and deletion of the furin cleavage site in the SARS-CoV-2 spike protein. This design introduces 283 silent mutations that slow viral replication without altering viral proteins, resulting in significant attenuation and enhanced safety. Unlike spike-only vaccines, COVI-VAC presents all SARS-CoV-2 antigens in their native conformation, potentially providing broader immunity and reducing susceptibility to immune escape from emerging variants. The vaccine is administered as a single intranasal dose and has demonstrated immunogenicity, safety, minimal viral shedding, and protection against both homologous and heterologous SARS-CoV-2 challenge in preclinical models. It is currently undergoing clinical development for the prevention of COVID-19[1][2][3][5][6][7].
- Brand names
- COVI-VACCovi-Vax
- Other names
- CDX-005CDX005CDX 005Covi-Vax
02
Targets
ACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on COVI-VAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVI-VAC.